HCPCS J0850: Cytomegalovirus Immune Globulin IV, per Vial

HCPCS Level II code J0850 denotes a vial of cytomegalovirus immune globulin intravenous (human), an infused biologic used to provide passive immunity against cytomegalovirus. Nationally, this injectable product is relevant in transplant medicine and for certain immunocompromised patients where CMV prophylaxis or treatment is indicated, making its billing and coverage practices important for hospitals and infusion centers.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for J0850, typical sites of service where the product is administered, and what to expect in payer coverage terms. The publication summarizes available benchmarks, common billing practices, and notable policy or coverage updates that affect reimbursement and utilization for this biologic. Practical guidance on where to locate related payer policies and billing considerations for infusion services is provided.

Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.

Customize your policy alerts

Sign up for hcpcs J0850 policy alerts

Get alerted when payer policies referencing J0850 are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Billing Code Overview

HCPCS Level II code J0850 represents injection, cytomegalovirus immune globulin intravenous (human), per vial. This code denotes a parenteral biologic product intended for intravenous administration to provide passive immunity against cytomegalovirus.

Service type: Intravenous infusion / injectable biologic
Typical site of service: Inpatient hospital, outpatient hospital infusion center, ambulatory infusion center, or other medical office/clinic settings where intravenous biologic administration is performed

Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.

Explore openpayer tools

View all tools

HCPCS J0850: Cytomegalovirus Immune Globulin IV, per Vial

Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.

Customize your policy alerts

Sign up for hcpcs J0850 policy alerts

Get alerted when payer policies referencing J0850 are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Billing Code Overview

Service type: Intravenous infusion / injectable biologic
Typical site of service: Inpatient hospital, outpatient hospital infusion center, ambulatory infusion center, or other medical office/clinic settings where intravenous biologic administration is performed

Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.

Clinical & Coding Specifications

Clinical Context

A 45-year-old solid-organ transplant recipient (renal transplant) is admitted for prophylaxis and treatment of cytomegalovirus (CMV) infection. The patient is CMV seropositive donor to seronegative recipient (D+/R−) and develops CMV viremia with rising viral load despite oral antiviral therapy intolerance or contraindication. Intravenous cytomegalovirus immune globulin (CMV-IVIG) is ordered as adjunctive therapy.

The clinical workflow: the transplant infectious disease clinician documents the indication and dose in the medical record. Pharmacy obtains and prepares the J0850 vial(s) under sterile conditions, labels them with lot number and expiration, and records them in the patient’s medication administration record. The nurse verifies consent and IV access, administers premedication if needed (antipyretic/antihistamine), and infuses CMV-IVIG per institutional infusion protocol while monitoring for infusion reactions. Post-infusion documentation includes lot numbers, vial count, administration time, infusion rate, patient tolerance, and any adverse reactions. Billing captures the number of vials administered using HCPCS J0850 with appropriate modifier(s) to reflect circumstances of service or drug handling.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`B25.9`	Cytomegalovirus disease, unspecified	Primary diagnosis for symptomatic CMV infection warranting IV immune globulin in severe or refractory cases.
`B25.2`	Cytomegalovirus pneumonitis	CMV lung infection in immunocompromised patients where CMV-IVIG may be used adjunctively.
`B25.0`	Cytomegaloviral hepatitis	Severe hepatic CMV infection where adjunctive immune globulin may be considered.
`B25.8`	Other cytomegalovirus disease	Includes CMV manifestations (e.g., gastrointestinal) potentially treated with CMV-IVIG adjunctively.
`T86.10`	Unspecified complication of kidney transplant	Post-transplant complications including CMV infection management context.
`T86.12`	Infection and inflammatory reaction of transplanted kidney	Relevant when CMV contributes to infection in transplanted organ.
`Z94.0`	Kidney transplant status	Denotes transplant recipient status, increasing CMV risk and need for prophylactic/therapeutic IVIG.
`D80.9`	Immunodeficiency, unspecified	Underlying immunodeficiency increasing susceptibility to CMV and need for passive immunization.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	Commonly used to report the infusion administration time for the first hour when CMV-IVIG is given in an outpatient infusion center.
`96366`	Intravenous infusion, each additional hour (List separately in addition to code for primary service)	Used to report additional infusion time beyond the first hour when CMV-IVIG administration exceeds 1 hour.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	May be used if a smaller dose is administered via subcutaneous or intramuscular route in an atypical scenario (rare for CMV-IVIG).
`36415`	Collection of venous blood by venipuncture	Often performed for pre-infusion viral load, serologies, or monitoring labs related to CMV treatment.
`99214`	Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	Represents the outpatient visit when the prescribing clinician evaluates the patient and documents the need for CMV-IVIG.

Related Modifiers

7 rows

Modifier
22
23
52
53
62
78
80

Related Provider Taxonomies

8 rows

Taxonomy Code
207K00000X
363L00000X
163W00000X
364S00000X
363LP0222X
156F00000X
364SP0809X
363LP2300X

Related Codes

HCPCS-J0013-ESKETAMINE-NASAL-SPRAY-1MG

HCPCS Level II J0013: Esketamine Nasal Spray, 1 mg

HCPCS-J0120-INJECTION-TETRACYCLINE-250MG

HCPCS J0120: Injection, Tetracycline, Up to 250 mg

HCPCS-J0121-OMADACYCLINE-INJECTION-1MG

HCPCS J0121: Omadacycline Injection, 1 mg

HCPCS-J0122-ERAVACYCLINE-INJECTION-1MG

HCPCS J0122: Injection, Eravacycline, 1 mg

HCPCS-J0129-ABATACEPT-INJECTION-10MG-PHYSICIAN-SUPERVISED

HCPCS J0129: Abatacept Injection, 10 mg

HCPCS-J0130-INJECTION-ABCIXIMAB-10MG

HCPCS Level II J0130: Injection abciximab, 10 mg

HCPCS-J0131-INJECTION-ACETAMINOPHEN-10MG-PARENTERAL-ANALGESIC

HCPCS J0131: Injection Acetaminophen, 10 mg

HCPCS-J0132-INJECTION-ACETYLCYSTEINE-100MG-INJECTABLE-MEDICATION

HCPCS J0132: Injection, Acetylcysteine 100 mg

HCPCS-J0133-ACYCLOVIR-INJECTION-5MG

HCPCS J0133: Injection, Acyclovir 5 mg

HCPCS-J0134-ACETAMINOPHEN-INJECTION-FRESENIUS-KABI-10MG

HCPCS J0134: Injection, Acetaminophen (Fresenius Kabi), 10 mg

Showing 1–10 of 991

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Explore openpayer tools

View all tools

Clinical & Coding Specifications

Clinical Context

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`B25.9`	Cytomegalovirus disease, unspecified	Primary diagnosis for symptomatic CMV infection warranting IV immune globulin in severe or refractory cases.
`B25.2`	Cytomegalovirus pneumonitis	CMV lung infection in immunocompromised patients where CMV-IVIG may be used adjunctively.
`B25.0`	Cytomegaloviral hepatitis	Severe hepatic CMV infection where adjunctive immune globulin may be considered.
`B25.8`	Other cytomegalovirus disease	Includes CMV manifestations (e.g., gastrointestinal) potentially treated with CMV-IVIG adjunctively.
`T86.10`	Unspecified complication of kidney transplant	Post-transplant complications including CMV infection management context.
`T86.12`	Infection and inflammatory reaction of transplanted kidney	Relevant when CMV contributes to infection in transplanted organ.
`Z94.0`	Kidney transplant status	Denotes transplant recipient status, increasing CMV risk and need for prophylactic/therapeutic IVIG.
`D80.9`	Immunodeficiency, unspecified	Underlying immunodeficiency increasing susceptibility to CMV and need for passive immunization.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	Commonly used to report the infusion administration time for the first hour when CMV-IVIG is given in an outpatient infusion center.
`96366`	Intravenous infusion, each additional hour (List separately in addition to code for primary service)	Used to report additional infusion time beyond the first hour when CMV-IVIG administration exceeds 1 hour.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	May be used if a smaller dose is administered via subcutaneous or intramuscular route in an atypical scenario (rare for CMV-IVIG).
`36415`	Collection of venous blood by venipuncture	Often performed for pre-infusion viral load, serologies, or monitoring labs related to CMV treatment.
`99214`	Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	Represents the outpatient visit when the prescribing clinician evaluates the patient and documents the need for CMV-IVIG.

Related Modifiers

7 rows

Modifier
22
23
52
53
62
78
80

Related Provider Taxonomies

8 rows

Taxonomy Code
207K00000X
363L00000X
163W00000X
364S00000X
363LP0222X
156F00000X
364SP0809X
363LP2300X

Related Codes

HCPCS-J0013-ESKETAMINE-NASAL-SPRAY-1MG

HCPCS Level II J0013: Esketamine Nasal Spray, 1 mg

HCPCS-J0120-INJECTION-TETRACYCLINE-250MG

HCPCS J0120: Injection, Tetracycline, Up to 250 mg

HCPCS-J0121-OMADACYCLINE-INJECTION-1MG

HCPCS J0121: Omadacycline Injection, 1 mg

HCPCS-J0122-ERAVACYCLINE-INJECTION-1MG

HCPCS J0122: Injection, Eravacycline, 1 mg

HCPCS-J0129-ABATACEPT-INJECTION-10MG-PHYSICIAN-SUPERVISED

HCPCS J0129: Abatacept Injection, 10 mg

HCPCS-J0130-INJECTION-ABCIXIMAB-10MG

HCPCS Level II J0130: Injection abciximab, 10 mg

HCPCS-J0131-INJECTION-ACETAMINOPHEN-10MG-PARENTERAL-ANALGESIC

HCPCS J0131: Injection Acetaminophen, 10 mg

HCPCS-J0132-INJECTION-ACETYLCYSTEINE-100MG-INJECTABLE-MEDICATION

HCPCS J0132: Injection, Acetylcysteine 100 mg

HCPCS-J0133-ACYCLOVIR-INJECTION-5MG

HCPCS J0133: Injection, Acyclovir 5 mg

HCPCS-J0134-ACETAMINOPHEN-INJECTION-FRESENIUS-KABI-10MG

HCPCS J0134: Injection, Acetaminophen (Fresenius Kabi), 10 mg

Showing 1–10 of 991

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.